CHC Healthcare Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

CHC Healthcare Group wird ein Gewinn- und Umsatzwachstum von 58.2% bzw. 19.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 58.5% pro Jahr wachsen soll.

Wichtige Informationen

58.2%

Wachstumsrate der Gewinne

58.2%

EPS-Wachstumsrate

Healthcare Gewinnwachstum	18.0%
Wachstumsrate der Einnahmen	19.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	17 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

CHC Healthcare Group (TWSE:4164) Will Pay A Larger Dividend Than Last Year At NT$2

Jun 29

CHC Healthcare Group's (TWSE:4164) Dividend Will Be Increased To NT$2.01

Jun 15

If You Had Bought CHC Healthcare Group's (TPE:4164) Shares Five Years Ago You Would Be Down 36%

Mar 08

CHC Healthcare Group's (TPE:4164) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Feb 07

CHC Healthcare Group (TPE:4164) Share Prices Have Dropped 32% In The Last Five Years

Dec 07

Are CHC Healthcare Group's (TPE:4164) Statutory Earnings A Good Guide To Its Underlying Profitability?

Nov 22

Gewinn- und Umsatzwachstumsprognosen

TWSE:4164 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (TWD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	4,990	629	N/A	N/A	1
12/31/2024	3,493	312	561	1,061	2
6/30/2024	3,807	274	416	863	N/A
3/31/2024	3,734	342	580	1,232	N/A
12/31/2023	3,877	419	387	963	N/A
9/30/2023	3,283	302	-120	480	N/A
6/30/2023	3,362	360	-148	534	N/A
3/31/2023	3,168	376	-331	321	N/A
12/31/2022	2,974	357	-26	657	N/A
9/30/2022	2,992	409	197	873	N/A
6/30/2022	2,654	375	62	676	N/A
3/31/2022	2,405	337	124	717	N/A
12/31/2021	2,440	382	179	693	N/A
9/30/2021	2,098	294	43	795	N/A
6/30/2021	2,451	383	177	913	N/A
3/31/2021	2,641	400	280	898	N/A
12/31/2020	2,555	366	195	916	N/A
9/30/2020	2,630	396	747	1,245	N/A
6/30/2020	2,741	393	836	1,245	N/A
3/31/2020	2,875	407	1,015	1,401	N/A
12/31/2019	2,950	395	871	1,215	N/A
9/30/2019	3,003	402	121	444	N/A
6/30/2019	2,791	347	39	357	N/A
3/31/2019	2,733	366	-296	147	N/A
12/31/2018	2,507	323	-33	338	N/A
9/30/2018	2,463	37	33	391	N/A
6/30/2018	2,193	-39	77	454	N/A
3/31/2018	1,948	-142	N/A	420	N/A
12/31/2017	2,117	-87	N/A	294	N/A
9/30/2017	2,307	240	N/A	512	N/A
6/30/2017	2,242	232	N/A	445	N/A
3/31/2017	2,418	227	N/A	735	N/A
12/31/2016	2,205	159	N/A	845	N/A
9/30/2016	2,165	133	N/A	628	N/A
6/30/2016	2,366	185	N/A	786	N/A
3/31/2016	2,450	271	N/A	782	N/A
12/31/2015	2,395	227	N/A	576	N/A
9/30/2015	2,363	236	N/A	732	N/A
6/30/2015	2,176	205	N/A	612	N/A
3/31/2015	1,974	189	N/A	436	N/A
12/31/2014	2,091	266	N/A	634	N/A
9/30/2014	2,000	242	N/A	738	N/A
6/30/2014	2,240	326	N/A	596	N/A
3/31/2014	2,117	328	N/A	673	N/A
12/31/2013	2,063	297	N/A	867	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4164Das prognostizierte Gewinnwachstum (58.2% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: 4164Die Erträge des Unternehmens (58.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (18.7% pro Jahr).

Hohe Wachstumserträge: 4164Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 4164Die Einnahmen des Unternehmens (19.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (11.6% pro Jahr).

Hohe Wachstumseinnahmen: 4164Die Einnahmen des Unternehmens (19.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 4164 in 3 Jahren voraussichtlich hoch sein wird

CHC Healthcare Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 15%

Price target decreased by 8.6% to NT$69.00

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 17%

Price target decreased to NT$47.00

Price target decreased to NT$46.00

Recent updates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

CHC Healthcare Group to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$2.00 per share

CHC Healthcare Group (TWSE:4164) Will Pay A Larger Dividend Than Last Year At NT$2

CHC Healthcare Group's (TWSE:4164) Dividend Will Be Increased To NT$2.01

Dividend increased to NT$2.01

CHC Healthcare Group Approves Cash Dividend, Payable on August 1, 2024

Consensus revenue estimates fall by 15%

Price target decreased by 8.6% to NT$69.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CHC Healthcare Group has filed a Follow-on Equity Offering in the amount of TWD 139.7 million.

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CHC Healthcare Group, Annual General Meeting, Jun 12, 2024

Consensus EPS estimates fall by 14%

New minor risk - Profit margin trend

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 17%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Shareholder dilution

Upcoming dividend of NT$1.97 per share at 2.9% yield

Investor sentiment improves as stock rises 15%

CHC Healthcare Group Announces Sustainability Committee Changes

CHC Healthcare Group Announces Change of Audit Committee

CHC Healthcare Group announced a financing transaction

Now 25% undervalued

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Price target decreased to NT$47.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to NT$46.00

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$2.01 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Third quarter 2021 earnings released: EPS NT$0.43 (vs NT$1.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.47 (vs NT$0.64 in 2Q 2020)

Director Yung-Shun Chuang has joined 7th company board

Upcoming dividend of NT$2.01 per share

First quarter 2021 earnings released: EPS NT$0.67 (vs NT$0.51 in 1Q 2020)

CHC Healthcare Group. Announces the Appointment of Pei-Lin Lee as CIO & CHRO of the Company, Effective March 19, 2021

CHC Healthcare Group, Annual General Meeting, Jun 16, 2021

Full year 2020 earnings released: EPS NT$2.53 (vs NT$2.83 in FY 2019)

If You Had Bought CHC Healthcare Group's (TPE:4164) Shares Five Years Ago You Would Be Down 36%

CHC Healthcare Group's (TPE:4164) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Should CHC Healthcare Group (TPE:4164) Be Part Of Your Dividend Portfolio?

New 90-day low: NT$36.80

Is CHC Healthcare Group (TPE:4164) Likely To Turn Things Around?

Is CHC Healthcare Group (TPE:4164) Using Too Much Debt?

CHC Healthcare Group (TPE:4164) Share Prices Have Dropped 32% In The Last Five Years

Are CHC Healthcare Group's (TPE:4164) Statutory Earnings A Good Guide To Its Underlying Profitability?

CHC Healthcare Group Announces Board Appointments

Third quarter 2020 earnings released: EPS NT$1.08

New 90-day low: NT$37.30

New 90-day low: NT$37.90

New 90-day low - NT$39.10

First half earnings released

First half earnings released

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken